DiaMedica Therapeutics Inc (DMAC)

DiaMedica Therapeutics Inc (DMAC) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $449M; returns 1 day +1.0%, 1 week +15.2%, 1 year +29.0%.

DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company focused on developing novel treatments for ischemic diseases, primarily acute ischemic stroke (AIS) and preeclampsia (PE). Their lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1 (rhKLK1), a synthetic version of a naturally occurring enzyme.

Groups DMAC belongs to

• Clinical Stage Biotech
• Biotechnology
• Biopharmaceutical
• Healthcare
• Clinical Stage
• Pharmaceuticals
• CNS Disorders
• Life Sciences

DMAC financial model: income statement, cash flow and balance sheet